Epithermal Neutron Beam Design for Neutron Capture Therapy at the Power Burst Facility and the Brookhaven Medical Research Reactor
Epithermal Neutron Beam Design for Neutron Capture Therapy at the Power Burst Facility and the Brookhaven Medical Research Reactor
复制标题
动力爆发设施和布鲁克海文医学研究堆中子捕获治疗的超热中子束设计
DOI：
10.13182/nt90-a34490
复制
发表时间：
1990
影响因子：
1.5
通讯作者：
D. Nigg
中科院分区：
文献类型：
--
作者：
F. Wheeler;D. Parsons;B. L. Rushton;D. Nigg
用中子俘获疗法(NCT)治疗癌症的两个反应堆超热中子束已经进行了核设计研究。布鲁克海文医学研究反应堆(BMRR)已经设计并实施了一种中等强度的超热光束。测量结果表明，BMRR对该束流主要特性的设计预测是准确的。BMRR目前正在进行一项研究NCT生物效应的犬类项目。爱达荷州国家工程实验室的功率爆发设施(PBF)最终确定了一种高强度超热光束的设计，该光束对不需要的辐射部件的污染最小。当确定人体NCT试验是可取的时，该设计将被实施。与BMRR相比，PBF束流的绝对超热通量强度将有大约一个数量级的改善，其角分布和光谱特性将更有利于NCT。射束强度、角度分布、光谱和污染水平的综合影响使得所需的肿瘤放射剂量可以在比目前可用的BMRR射束更短的时间内被提供，并且由于射束污染而使侧支剂量显著减少(3到5倍)。
Nuclear design studies have been performed for two reactor-based epithermal neutron beams for cancer treatment by neutron capture therapy (NCT). An intermediate-intensity epithermal beam has been designed and implemented at the Brookhaven Medical Research Reactor (BMRR). Measurements show that the BMRR design predictions for the principal characteristics of this beam are accurate. A canine program for research into the biological effects of NCT is now under way at BMRR. The design for a high-intensity epithermal beam with minimal contamination from undesirable radiation components has been finalized for the Power Burst Facility (PBF) at the Idaho National Engineering Laboratory. This design will be implemented when it is determined that human NCT trials are advisable. The PBF beam will exhibit approximately an order of magnitude improvement in absolute epithermal flux intensity over that available in the BMRR, and its angular distribution and spectral characteristics will be more advantageous for NCT. The combined effects of beam intensity, angular distribution, spectrum, and contaminant level allow the desired tumor radiation dose to be delivered in much shorter times than are possible with the currently available BMRR beam, with a significant reduction (factor of 3 to 5) in collateral dose due to beam contaminants.